Galectin-1 pulls the strings on VEGFR2

Research output: Contribution to journalShort surveypeer-review

18 Scopus citations


Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

Original languageEnglish (US)
Pages (from-to)625-626
Number of pages2
Issue number4
StatePublished - Feb 13 2014

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Galectin-1 pulls the strings on VEGFR2'. Together they form a unique fingerprint.

Cite this